117 related articles for article (PubMed ID: 33742407)
1. In Vivo Assessment of Metastatic Cell Potential in Prostate Cancer.
Nunez-Olle M; Guiu M; Gomis RR
Methods Mol Biol; 2021; 2294():253-267. PubMed ID: 33742407
[TBL] [Abstract][Full Text] [Related]
2. Models of Prostate Cancer Bone Metastasis.
Park SH; Eber MR; Shiozawa Y
Methods Mol Biol; 2019; 1914():295-308. PubMed ID: 30729472
[TBL] [Abstract][Full Text] [Related]
3. Animal models of bone metastasis.
Rosol TJ; Tannehill-Gregg SH; LeRoy BE; Mandl S; Contag CH
Cancer; 2003 Feb; 97(3 Suppl):748-57. PubMed ID: 12548572
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
5. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Singh AS; Macpherson GR; Price DK; Schimel D; Figg WD
Oncol Rep; 2006 Mar; 15(3):519-24. PubMed ID: 16465406
[TBL] [Abstract][Full Text] [Related]
7. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
8. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive microCT imaging characterization and in vivo targeting of BB2 receptor expression of a PC-3 bone metastasis model.
Winkelmann CT; Figueroa SD; Sieckman GL; Rold TL; Hoffman TJ
Mol Imaging Biol; 2012 Dec; 14(6):667-75. PubMed ID: 22314281
[TBL] [Abstract][Full Text] [Related]
10. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.
Fong EL; Wan X; Yang J; Morgado M; Mikos AG; Harrington DA; Navone NM; Farach-Carson MC
Biomaterials; 2016 Jan; 77():164-72. PubMed ID: 26599623
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of metastatic potential in prostate carcinoma: an in vivo model.
Angelucci A; Gravina GL; Rucci N; Festuccia C; Muzi P; Vicentini C; Teti A; Bologna M
Int J Oncol; 2004 Dec; 25(6):1713-20. PubMed ID: 15547709
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of bone metastasis model of prostate cancer in nude mice by intratibia injection of human prostate cancer cell line Du145].
Luo Y; Zhang LL; Ning L; He DL; Fan JH; Hou HL
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):133-6. PubMed ID: 16519149
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.
Yang Q; Lang C; Wu Z; Dai Y; He S; Guo W; Huang S; Du H; Ren D; Peng X
J Exp Clin Cancer Res; 2019 Sep; 38(1):391. PubMed ID: 31488180
[TBL] [Abstract][Full Text] [Related]
15. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
17. [Construction and improvement of animal models with different positional osseous metastasis of prostate cancer in vivo].
Bi YX; Xiao MH; Zhang NN; Li XY; Mao XP; Zhang K; Zhang ZR; Zhao LY
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):590-596. PubMed ID: 28816271
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
19. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]